research use only

Motixafortide (BL-8040, BKT140) CXCR4 Antagonist

Name: Motixafortide (BL-8040, BKT140)
Brand: Selleck Chemicals
SKU: S9665
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S9665

Motixafortide (BL-8040, BKT140, TF 14016, 4-fluorobenzoyl, 4F-benzoyl-TN14003, T140) is an antagonist of CXCR4 with IC50 of ～1 nM. BL-8040 induces the apoptosis of AML blasts by down-regulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression.

Chemical Structure

Molecular Weight: 2159.52

Jump to

Quality Control

Batch: Purity: 99.36%

99.36

Related Targets	PD-1/PD-L1 STING AhR Immunology & Inflammation related CD markers Interleukins Anti-infection Antioxidant COX Histamine Receptor
Other CXCR Inhibitors	AZD5069 SB 225002 Reparixin (Repertaxin) WZ811 Navarixin (SCH-527123) LIT-927 AMG 487 SX-682 SB 265610 LY2510924

Solubility

In vitro
Batch:

Water : 100 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5.000mg/ml (2.32mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.625mg/ml (0.29mM)	Taking the 1 mL working solution as an example, add 50 μL of 12.5 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	2159.52	Formula	C₉₇H₁₄₄FN₃₃O₁₉S₂	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	664334-36-5	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	BKT140, TF 14016, 4-fluorobenzoyl, 4F-benzoyl-TN14003, T140			SMILES	C1CC2C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2C1)CCCCN)CCCCN)CCCNC(=O)N)CC3=CC=C(C=C3)O)NC(=O)C(CC4=CC5=CC=CC=C5C=C4)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C6=CC=C(C=C6)F)C(=O)NC(CCCNC(=N)N)C(=O)N)CCCNC(=O)N)CCCNC(=N)N)CC7=CC=C(C=C7)O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	ERK Bcl-2 MCL-1 cyclin-D1 CXCR4 (Cell-free assay) 1 nM
In vitro	Treatment with Motixafortide (BL-8040) induces the robust mobilization of AML blasts from the BM. In addition, AML cells exposed to this compound undergo differentiation. It also induces the apoptosis of AML cells in vitro. This apoptosis is mediated by the up-regulation of miR-15a/miR-16-1, resulting in down-regulation of the target genes BCL-2, MCL-1 and cyclin-D1. Overexpression of miR-15a/miR-16-1 directly induces leukemic cell death. BL-8040-induced apoptosis is also mediated by the inhibition of survival signals via the AKT/ERK pathways.
In vivo	Motixafortide (BL-8040) induces the apoptosis of AML cells in vivo. This compound also synergizes with FLT3 inhibitors to induce AML cell death. Treatment with a BCL-2 inhibitor induces apoptosis and acts together with it to enhance cell death. Importantly, this combined treatment prolongs the survival of tumor-bearing mice and reduces minimal residual disease in vivo.
References	[1] https://pubmed.ncbi.nlm.nih.gov/28280274/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-05-05)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06506461	RECRUITING	Sickle Cell Disease	St. Jude Children's Research Hospital	2025-03-21	PHASE1
NCT07392970	RECRUITING	Acute Myeloid Leukemia; Measurable Residual Disease	Washington University School of Medicine	2026-07-23	PHASE2
NCT04543071	RECRUITING	Pancreatic Cancer; Adenocarcinoma of the Pancreas; Adenocarcinoma	Gulam Manji	2020-11-09	PHASE2
NCT06442761	RECRUITING	Sickle Cell Disease	St. Jude Children's Research Hospital	2024-11-14	PHASE1
NCT06514508	RECRUITING	Multiple Myeloma	Guangzhou Gloria Biosciences Co., Ltd.	2025-12-01	PHASE3
NCT07101445	RECRUITING	Multiple Myeloma	Emory University	2025-09-24	PHASE4

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):